|
Fusion Antibodies PLC on Wednesday said it was selected to proceed with three follow on projects to the stable Cell Line Development project. The Belfast-based contract researcher that provides discovery, design and optimisation services for therapeutic antibodies to the healthcare market in February had announced the project, under which it generates the definitive cell line for future production of the therapeutic product. Back then, Fusion Antibodies had said that the agreement was expected to result in the company generating revenue of around $250,000 by the end of 2025. The new contracts announced on Wednesday are valued at around $460,000, of which at least $400,000 is expected to be recognised in the current financial year that ends on March 31, 2026. Chief Executive Officer Adrian Kinkaid said: ‘We are delighted to extend our agreement with this significant client and to add a further earlier stage project to the pipeline of work we are undertaking with them. We look forward to continuing to work with our client to bring better antibodies to the clinic more rapidly. These new contracts and the CLD project highlights the strong reputation that Fusion has for delivering high quality therapeutic antibodies and their associated cell lines: a part of our offering with excellent scope for growth.’ Fusion Antibodies shares rose 3.3% to 15.50 pence each on Wednesday afternoon in London. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
